BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260409T203000
DTSTAMP:20260423T191025
CREATED:20260407T093519Z
LAST-MODIFIED:20260407T094833Z
UID:41540-1775761200-1775766600@kesho-kenya.org
SUMMARY:Treatment in Esophageal Cancer
DESCRIPTION:THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer \nDate: 9th April 2026 Time: 7 PM – 8:30 PM EAT \nMODERATOR \nDr. Omar Abdihamid Clinical Oncologist\, Garissa Regional Cancer Center | Vice President (EA)\, African Organisation for Research and Training in Cancer \nSPEAKERS \nDr. Juma Odoro Cardiothoracic and vascular surgeon\, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer \nDr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer \nDr. Kevin Makori Consultant Clinical & Radiation Oncologist\, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator\, Victoria Cancer Care & Research Center\, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-04-07-at-12.13.58-PM-e1775554431579.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260326T190000
DTEND;TZID=Africa/Nairobi:20260326T203000
DTSTAMP:20260423T191025
CREATED:20260324T112204Z
LAST-MODIFIED:20260324T112936Z
UID:41493-1774551600-1774557000@kesho-kenya.org
SUMMARY:Optimizing Care in Colorectal Cancer
DESCRIPTION:Date: 26th March 2026 \nTime: 7 PM – 8:30 PM EAT \nModerator \n\nDr. Andrew Odhiambo Medical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\n\nSpeakers \nDr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist\, Kenyatta University Teaching\, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment \nDr. Caroline Tonio Medical Oncologist\, Clinical Research Fellow (Clinical Trials)\, The Christie NHS Foundation Trust\, UK & KUTRRH\, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact. \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/optimizing-care-in-colorectal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-24-at-8.25.12-AM-e1774351309301.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260319T190000
DTEND;TZID=Africa/Nairobi:20260319T203000
DTSTAMP:20260423T191025
CREATED:20260318T112347Z
LAST-MODIFIED:20260319T174535Z
UID:41463-1773946800-1773952200@kesho-kenya.org
SUMMARY:Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
DESCRIPTION:Evidence-Based Integration of Surgery and Systemic Therapy \nDate: 19th March 2026Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Amina K. HabibMedical Oncologist\, Aga Khan University Hospital\, Nairobi \nDr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma \nDr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma \nHighlights\nThis session examined the evolving management of renal cell carcinoma (RCC)\, focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum. \nA central theme was the importance of risk-adapted\, multidisciplinary care\, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally\, late-stage presentation remains common in Kenya\, shaping both prognosis and treatment strategy. \nFrom a surgical perspective\, nephron-sparing surgery remains standard for localized diseases\, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease\, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients\, particularly when integrated with systemic treatment strategies. \nSystemic therapy has expanded significantly\, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens\, reinforcing a shift towards early and strategic use of systemic therapy\, particularly in metastatic and high-risk settings. \nIn the adjuvant setting\, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients\, highlighting the importance of post-surgical risk stratification and follow-up. \nHowever\, translating these advances into routine practice remains constrained by access\, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways\, supported by multidisciplinary decision-making and strengthened health systems. \nAcross the session\, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery\, systemic therapy and patient-centered decision-making. \nKey Takeaways \n\nRCC management requires integration of surgical and systemic therapies.\nLate-stage presentation remains a key challenge in many settings.\nNephron-sparing and radical surgery remain central to localized and advanced disease.\nImmunotherapy and targeted agents are transforming metastatic RCC outcomes.\nAdjuvant therapy is increasingly relevant in high-risk post-surgical patients.\nAccess\, cost and infrastructure continue to shape real-world implementation.\n\n 
URL:https://kesho-kenya.org/event/renal-cell-carcinoma-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-18-at-10.33.25-AM-e1773833004541.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260312T190000
DTEND;TZID=Africa/Nairobi:20260312T203000
DTSTAMP:20260423T191025
CREATED:20260310T140249Z
LAST-MODIFIED:20260319T174323Z
UID:41385-1773342000-1773347400@kesho-kenya.org
SUMMARY:Multiple Myeloma Care in Western Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Event Title: The Journey of Multiple Myeloma Care in Western Kenya \nAccreditation: CPD Accredited \n\nDate: 12th March 2026\nTime: 7 PM – 8:30 PM EAT\nOrganization: KESHO (Kenya Society of Haematology & Oncology)\n\nModerator:  \n\nDr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist\, Kenyatta National Hospital.\n\nSpeakers \n\n\n\n\nDr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification \nDr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing\, Cellular Therapies and Risk-Adapted Strategies \nDr. Beatrice Melly: Clinical Haematologist\, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access\, Infrastructure and Multidisciplinary Integration \nHightlights\n\n\n\n\n\n\n\n\nThis session examined how multiple myeloma care is evolving within the Kenyan context\, bringing together perspectives on diagnostics\, treatment advances and system-level delivery. \nA central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors\, immunomodulatory agents and anti-CD38 therapies\, translating these gains into routine practice remains uneven. \nThe discussion highlighted the importance of accurate and timely diagnosis\, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions. \nFrom a clinical perspective\, modern management is increasingly risk-adapted\, incorporating quadruplet induction regimens\, autologous stem cell transplantation and maintenance strategies. Emerging therapies\, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease\, though access remains limited in many settings. \nAt a systems level\, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships\, integrating clinical care\, training and research within a learning health system. The approach emphasizes improving access\, strengthening diagnostic and treatment infrastructure\, and embedding multidisciplinary care pathways to support patients across the disease course. \nAcross the session\, a consistent message emerged: advancing myeloma care requires not only better therapies\, but systems capable of delivering them. \nKey Takeaways \n\nMyeloma outcomes are improving with novel and combination therapies.\nAccurate diagnosis and risk stratification are central to management.\nStandard care includes quadruplet induction\, ASCT and maintenance therapy.\nCAR-T and bispecific antibodies are reshaping relapsed disease care.\nSustainable progress depends on access\, infrastructure and integrated care models.
URL:https://kesho-kenya.org/event/multiple-myeloma-care-in-western-kenya/
CATEGORIES:CME 2026,Conferences,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-10-at-11.40.58-AM-1-e1773151318490.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260305T190000
DTEND;TZID=Africa/Nairobi:20260305T203000
DTSTAMP:20260423T191025
CREATED:20260303T081324Z
LAST-MODIFIED:20260303T083141Z
UID:41277-1772737200-1772742600@kesho-kenya.org
SUMMARY:Women in Oncology
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nWomen in Oncology this International Women’s Day! \nJoin us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology \nDate: 5th March 2026 \nTime: 7:00 PM – 8:30 PM EAT \nModerator: \n\nDr. Gladwell Kiarie — Medical Oncologist\, The Nairobi Hospital\n\nSpeakers: \n\nProf. Verna Vanderpuye\n\nSenior Consultant Clinical Oncologist & Deputy Director\, National Centre of Radiotherapy\, Oncology and Nuclear Medicine\, Korle-bu Teaching Hospital\, Accra\, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa \n\nDr. Chemtai Mungo\n\nAssistant Professor of Obstetrics and Gynaecology & Physician-Scientist\, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health\, Research and Women’s Impact in Oncology \n\nDr. Anne Mwirigi\n\nConsultant Haematologist and Assistant Professor\, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology \n\nProf. Nazik Hammad\n\nProfessor of Medical Oncology\, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship\, Leadership and Equity in Cancer Care[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_2lIM-Q1-Rm6JSxlo9b0jmQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/women-in-oncology-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-03-at-8.06.46-AM-e1772525890478.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260226T190000
DTEND;TZID=Africa/Nairobi:20260226T203000
DTSTAMP:20260423T191025
CREATED:20260223T194335Z
LAST-MODIFIED:20260319T173215Z
UID:41036-1772132400-1772137800@kesho-kenya.org
SUMMARY:Precision Pathways in Lymphoma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT) \n\nSpeakers \nModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor\, AKUH \nDr Rohini RadiaConsultant in BMT and Haematology\, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence \nDr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor\, AKUHLymphoma Diagnostic Algorithm in Routine Practice \nHighlights\nThis session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making\, particularly in settings where access to advanced diagnostics remains variable. \nA central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach\, integrating clinical context\, histopathology\, immunophenotyping and where available\, molecular profiling. As emphasized during the discussion\, classification is no longer purely descriptive: it directly determines treatment pathways\, prognosis and eligibility for emerging therapies. \nDr. Wawire outlined a structured diagnostic framework anchored on architecture\, cytology and clonality\, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice\, a focused IHC panel (CD20\, CD3\, CD5\, CD10\, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions. \nImportantly\, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed. \nBuilding on this\, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics\, treatment selection and delivery systems. In practice\, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology\, oncology and imaging essential. \nAs treatment options expand\, from immunochemotherapy to targeted agents\, CAR-T therapies and bispecific antibodies\, the need for early risk stratification and timely decision-making becomes even more critical\, particularly in balancing efficacy\, cost and access within real-world settings. \nAcross the case discussions\, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care. \nKey takeaways: \n\nLymphoma classification now relies on integrated clinical\, morphological and molecular assessment.\nFocused IHC panels remain highly effective in routine and resource-limited settings.\n“NFC” supports safe\, transparent reporting when advanced testing is unavailable.\nDiagnostic delays and access gaps can directly impact treatment decisions.\nEarly alignment across disciplines is essential to optimize outcomes.
URL:https://kesho-kenya.org/event/precision-pathways-in-lymphoma/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-23-at-10.02.59-PM-e1771875762948.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260219T190000
DTEND;TZID=Africa/Nairobi:20260219T203000
DTSTAMP:20260423T191025
CREATED:20260218T181534Z
LAST-MODIFIED:20260407T102753Z
UID:40973-1771527600-1771533000@kesho-kenya.org
SUMMARY:Management of Biliary and Gall Bladder Tumours
DESCRIPTION:SUMMARY \nAdvances in the Multidisciplinary Management of Biliary and Gallbladder Tumours \nSpeakers: Prof. Elly Ogutu\, Dr. Mohan Ramchandani\, Dr. Kausik Bhattacharya\, Dr. M. Vamshi Krishna \nDate: 19 February 2026 \nThis session examined the management of biliary and gallbladder tumours through a multidisciplinary lens\, highlighting the importance of coordinated approaches across endoscopy\, surgery and oncology in improving patient outcomes. \nA central theme was the role of accurate and timely diagnosis\, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes. \nThrough the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology\, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills. \nFrom a clinical perspective\, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care\, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning. \nAcross the session\, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated\, multidisciplinary care across the patient journey. \nKey Takeaways \n\nEarly and accurate diagnosis remains central to effective management.\nAdvanced endoscopic techniques play a key role in tissue sampling and staging.\nMultidisciplinary coordination improves treatment planning and outcomes.\nRegional and diaspora collaboration strengthens clinical capacity.\nIntegration of surgical\, endoscopic and oncological care is essential.
URL:https://kesho-kenya.org/event/management-of-biliary-and-gall-bladder-tumours/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-18-at-10.47.07-AM-e1771438592764.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260212T080000
DTEND;TZID=Africa/Nairobi:20260212T170000
DTSTAMP:20260423T191025
CREATED:20251222T170033Z
LAST-MODIFIED:20260407T085208Z
UID:40759-1770883200-1770915600@kesho-kenya.org
SUMMARY:Environmental Risks of Cancer
DESCRIPTION:Speakers: Dr. Mary Nyangasi\, Dr. David Githanga\, Dr. Carolina Espina\nDate: 12 February 2026 \nHighlights\nThis session examined cancer risk through an environmental and public health lens\, highlighting the extent to which cancer burden is shaped by modifiable exposures rather than biology alone. A central theme was the recognition that cancer is not only a clinical or genetic condition\, but also a social and environmental disease\, with a substantial proportion of cases linked to preventable risk factors. Global evidence suggests that up to 40% of cancers are attributable to modified exposures\, including environmental and occupational risks. Dr. Githanga outlined the biological mechanisms through which environmental exposures drive carcinogenesis\, including DNA damage\, chronic inflammation\, epigenetic dysregulation and impaired immune surveillance. These pathways act cumulatively over time\, often with long latency periods between exposure and disease manifestation. \nReal-world examples such as air pollution\, aflatoxin exposure and oncogenic infections illustrate how environmental context directly shapes cancer patterns\, particularly in low- and middle-income settings where exposure levels are higher and regulatory systems less robust. Building on this\, Dr. Nyangasi emphasized that a significant proportion of cancer burden is preventable\, with WHO frameworks highlighting the importance of population-level interventions targeting modifiable risk factors\, including environmental regulation\, vaccination and lifestyle-related risks. \nDr. Espina introduced the World Code Against Cancer framework\, which translates complex scientific evidence into clear\, actionable recommendations for individuals\, health systems and policymakers. The framework underscores the importance of moving beyond individual behavior change towards coordinated\, multi-sectoral prevention strategies. Across the session\, a consistent message emerged: meaningful reductions in cancer burden will depend on shifting upstream towards prevention\, regulation and system-level action \nKey Takeaways  \n\nA substantial proportion of cancers are linked to modifiable environmental and behavioral exposures.\nEnvironmental carcinogenesis occurs through multi-pathway biological mechanisms over time.\nExposure to risk is uneven and shaped by social and economic conditions.\nPopulation-level interventions have greater impact than individual behavior change alone.\nEffective cancer control requires alignment between clinical practice\, public health and policy.
URL:https://kesho-kenya.org/event/environmental-risks-of-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/12/Environmental-Risks-of-Cancer.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260205T190000
DTEND;TZID=Africa/Nairobi:20260205T203000
DTSTAMP:20260423T191025
CREATED:20260203T112643Z
LAST-MODIFIED:20260319T172224Z
UID:40841-1770318000-1770323400@kesho-kenya.org
SUMMARY:World Cancer Day
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWorld Cancer Day: \nUnited by Unique – The Kenyan Perspective \nDate: 5th February 2025Time: 7:00 PM – 8:30 PM (EAT) \nModerator \nDr. Gladwell KiarieMedical Oncologist\, The Nairobi Hospital \nSpeakers \nHon. Dr. Ouma OlugaPrincipal Secretary for the State Department for Medical Services\,Ministry of Health\, Kenya \nHon. Dr. James NyikalChairperson of the National Assembly Departmental Committee on Health\, Kenya \nDr. Mercy MwangangiChief Executive Officer\, Social Health Authority \nDr. Elias MellyChief Executive Officer\, National Cancer Institute\, Kenya \nDr. Ahmed OgwellPublic Health Expert\, CEO & President\, VillageReach \nPrisca GithukaVice-Chairperson & Advocacy Chair\,Kenyan Network of Cancer Organizations (KENCO) and Chairlady\,Cancer Survivors Association of Kenya \nHighlights\nThis session brought together clinical\, policy and advocacy voices to reflect on the current state of cancer care in Kenya\, with a focus on how systems\, leadership and lived experience intersect to shape outcomes. \nA central theme was the need to move beyond fragmented approaches towards coordinated\, patient-centered cancer control\, grounded in national priorities and responsive to the realities of care delivery. The discussion highlighted that improving outcomes requires not only clinical excellence\, but also alignment across policy\, financing and implementation. \nSpeakers emphasized the importance of strengthening health systems to support prevention\, early detection and access to treatment\, while addressing structural barriers that continue to limit equitable care. The role of national institutions\, policy frameworks and cross-sector collaboration emerged as critical in driving sustainable progress. \nPatient voice and lived experience were also highlighted as essential to shaping responsive and inclusive cancer care strategies\, ensuring that interventions reflect the needs and realities of those most affected. \nAcross the discussion\, a consistent message emerged: meaningful progress in cancer control will depend on alignment between policy\, practice and people. \nKey Takeaways \n\nEffective cancer control requires alignment across clinical care\, policy and implementation.\nStrengthening health systems is essential to improving access\, equity and outcomes.\nPrevention and early detection remain critical entry points for reducing burden.\nPatient voice and lived experience are key to responsive\, person-centered care.\nSustainable progress depends on multi-sector collaboration and leadership.\n\nWatch the full session here: \n    	\n        Watch Video
URL:https://kesho-kenya.org/event/world-cancer-day/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-03-at-2.30.14-PM-e1770118388259.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260131T080000
DTEND;TZID=Africa/Nairobi:20260131T170000
DTSTAMP:20260423T191025
CREATED:20251222T165602Z
LAST-MODIFIED:20251223T153057Z
UID:40755-1769846400-1769878800@kesho-kenya.org
SUMMARY:HPV Vaccine  Campaign/Outreach Screening
DESCRIPTION:
URL:https://kesho-kenya.org/event/hpv-vaccine-campaign-outreach-screening/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260122T190000
DTEND;TZID=Africa/Nairobi:20260122T203000
DTSTAMP:20260423T191025
CREATED:20251222T165215Z
LAST-MODIFIED:20260319T171500Z
UID:40753-1769108400-1769113800@kesho-kenya.org
SUMMARY:Cervical Cancer Prevention and Control In Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \n(CPD Accredited) \nDate & Time: 22nd January 2026 7 PM – 8:30 PM (EAT) \n\nModerator: Dr. Benjamin Elly Odongo\nObstetrician/Gynecologist & Gynaecologic Oncologist\, Senior Lecturer & Chairman\, Department of Obstetrics & Gynaecology\, Kenyatta University School of Health Sciences\n\nSpeakers: \nProf. Lucy Muchiri\nAssociate Professor in the Department of Human Pathology\, University of Nairobi’s School of Medicine\nTopic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services \nProf. Omu Anzala Professor of Virology and Immunology\, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR)\, University of Nairobi\, Kenya\nTopic: HPV Vaccination in Kenya: Scientific Evidence\, Immunological Perspectives\, and Public Controversies \nDr. Richa Bansal Gynecological Oncologist and Robotic Surgeon\, Apollo Hospitals\, Navi Mumbai\, India\nTopic: Cervical Cancer Prevention and Advanced Treatment \nHighlights\nThis session examined cervical cancer through the lens of prevention\, highlighting it as one of the few cancers where elimination is both feasible and within reach. \nA central theme was the WHO 90-70-90 strategy\, which outlines a clear pathway to elimination through HPV vaccination\, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100\,000 women\, effectively transforming it into a rare disease. \nThe discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection\, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective\, with strong and sustained protection against high-risk HPV types responsible for most cases. \nDespite this\, the burden remains disproportionately high in low- and middle-income settings\, including Kenya\, where gaps in screening coverage\, diagnostic capacity and referral pathways continue to limit early detection and timely treatment. \nThe role of pathology services emerged as critical\, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing\, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets. \nAcross the session\, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works. \nKey Takeaways \n\nCervical cancer is one of the few cancers where elimination is achievable.\nThe WHO 90-70-90 targets provide a clear\, evidence-based roadmap.\nHPV vaccination and screening are high-impact prevention strategies.\nStrengthening pathology and diagnostic capacity is essential to progress.\nClosing gaps in access and coverage is critical to achieving equitable outcomes.
URL:https://kesho-kenya.org/event/cervical-cancer-prevention/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/01/WhatsApp-Image-2026-01-20-at-9.44.15-AM-e1768910604384.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251222T080000
DTEND;TZID=Africa/Nairobi:20251222T170000
DTSTAMP:20260423T191025
CREATED:20251222T171421Z
LAST-MODIFIED:20251223T152917Z
UID:40765-1766390400-1766422800@kesho-kenya.org
SUMMARY:Multiple Myeloma
DESCRIPTION:
URL:https://kesho-kenya.org/event/multiple-myeloma-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251211T190000
DTEND;TZID=Africa/Nairobi:20251211T203000
DTSTAMP:20260423T191025
CREATED:20251208T194713Z
LAST-MODIFIED:20251208T201236Z
UID:40719-1765479600-1765485000@kesho-kenya.org
SUMMARY:Bladder and Urothelial Cancer Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Moderator:  \nDr. Thomas OdenyMedical Oncologist\, Assistant Professor of Medicine\,Washington University in St. Louis \nSpeakers: \nDr. Primus OchiengLecturer\, Programme Director – MMed Radiation Oncology& Founder\, UNITED Oncology Clinical Trial Centre\, UoNRadiotherapy in Bladder Cancer: Current Evidence and Clinical Applications \nDr. DK KimaniConsultant Surgeon & Urologist\, Kenyatta National Hospital\, NairobiBladder & Urothelial Cancer in Kenya: Bridging Treatment Innovations and Local Realities \nDr. Andrea ApolloSenior Investigator\, Genitourinary Malignancies Branch\, NCI\, USAManagement of bladder cancer: Clinical trials and research updates \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_r-GmQ2UNQ5a2J_g3WFZKPg”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bladder-and-urothelial-cancer-treatment/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/12/Bladder-and-Urothelial-1-e1765223155779.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251204T190000
DTEND;TZID=Africa/Nairobi:20251204T203000
DTSTAMP:20260423T191025
CREATED:20251208T200234Z
LAST-MODIFIED:20251223T171606Z
UID:40728-1764874800-1764880200@kesho-kenya.org
SUMMARY:Cancer-Related Thrombosis
DESCRIPTION:Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis\nPresentation by Dr Laura Kirui\nDr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT)\, addressing its epidemiology\, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum. \nThe presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation\, dysregulated fibrinolysis\, and tumor host cellular interactions were reviewed to contextualize clinical risk. \nEmphasis was placed on risk stratification\, particularly the use of validated tools such as the Khorana score\, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed\, alongside bleeding considerations. The session also addressed therapeutic anticoagulation\, duration of treatment\, secondary prophylaxis and management in special scenarios including thrombocytopenia\, catheter-related thrombosis and incidental VTE. \nKey takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.
URL:https://kesho-kenya.org/event/cancer-related-thrombosis/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/12/WhatsApp-Image-2025-12-08-at-10.54.41-PM-e1765224285156.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251127T190000
DTEND;TZID=Africa/Nairobi:20251127T203000
DTSTAMP:20260423T191025
CREATED:20251125T134829Z
LAST-MODIFIED:20251125T135434Z
UID:40713-1764270000-1764275400@kesho-kenya.org
SUMMARY:Management of Pancreatic Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nCPD ACCREDITED \nManagement of Pancreatic Cancer \nDate:27th November 2025 \nTime:7 PM – 8:30 PM EAT \n\nModerator \nDr. Karan GandhiConsultant Hepatobiliary\, General and Laparoscopic Surgeon at 3rd Park Hospital\, Nairobi \n\nSPEAKER \nDr. Sakulen A HarguraConsultant Hepatobiliary\, General & Laparoscopic Surgeon\, Kenyatta University Teaching\, Research and Referral Hospital\, NairobiTopic: Surgical Dilemmas in Pancreatic Cancer\, “Who\, When & How” \n\nSPEAKER \nDr. Andrew OdhiamboMedical Oncologist – The Nairobi HospitalThematic Head & Program Director – Medical Oncology\, UONTopic: Balancing Quality Vs Quantity of Life – Oncologist Role in Stage 4 Pancreatic Cancer \nSPEAKER \nJoyce AwuorConsultant Dietitian Nutritionist\, Founder and CEO of DietSelect254Topic: The Ideal Diet for A Failing Pancreas \nKESHOKenya Society of Haematology & Oncology \n[/vc_column_text][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_LBsnGVB-T6u9uhilBFGe0w”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-pancreatic-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-25-at-10.01.18-AM-e1764078640953.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251120T190000
DTEND;TZID=Africa/Nairobi:20251122T203000
DTSTAMP:20260423T191025
CREATED:20251118T071137Z
LAST-MODIFIED:20251223T172117Z
UID:40558-1763665200-1763843400@kesho-kenya.org
SUMMARY:Management of Non-Small Cell Lung Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nBRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer \nDate: 20th November 2025Time: 7 PM – 8:30 PM EAT \n(CPD ACCREDITED) \n\nModerator\nDr. Muhindi WanjuguPhysician and Chest Specialist\, The Nairobi Hospital\, Doctors Plaza\, Nairobi \n\nSpeakers\nDr. Nuruddin JoomaHaemato-Oncologist\, Florida Cancer Specialists & Research Institute\, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer \nDr. Morris MuhingaConsultant Cardiothoracic Surgeon\, The Nairobi HospitalShift in Surgical Paradigm \nSummary: \nLung Cancer: Contemporary Clinical Management and Emerging Evidence \nPresentations by Dr Nuruddin Jooma and Dr Morris Muhinga \nThe sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management\, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early\, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification\, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing. \nKey clinical principles discussed included optimal diagnostic pathways incorporating imaging\, histopathology and immunohistochemistry\, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection\, avoid inappropriate use of immunotherapy and improve survival outcomes. \nCurrent standards of care were reviewed across disease stages\, including surgical management in early-stage disease\, the expanding role of neoadjuvant and adjuvant systemic therapies\, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms. \nBoth presentations reinforced the need for timely diagnosis\, biomarker-driven treatment decisions and coordinated multidisciplinary care\, while acknowledging ongoing challenges related to access\, treatment sequencing and long-term disease control. \nKey takeaway: Optimal lung cancer outcomes depend on precise staging\, comprehensive molecular testing and evidence-based\, multidisciplinary treatment across the disease continuum.
URL:https://kesho-kenya.org/event/management-of-non-small-cell-lung-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-17-at-10.34.44-PM-e1763449878610.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251113T190000
DTEND;TZID=Africa/Nairobi:20251113T203000
DTSTAMP:20260423T191025
CREATED:20251110T143627Z
LAST-MODIFIED:20251223T151933Z
UID:40551-1763060400-1763065800@kesho-kenya.org
SUMMARY:Advances in Small-Cell Lung Cancer Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 13th November 2025Time: 7 PM – 8:30 PM EAT \n\nSpeakerDr. Riaz KasmaniMedical Oncologist\, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances\, Evidence and Clinical Challenges \n\nModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head\, Pulmonology\, Aga Khan Hospital \n\nOrganized by:KESHOKenya Society of Haematology & Oncology \nSupported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nDr Kasmani presented an overview of Small Cell Lung Cancer (SCLC)\, focusing on disease biology\, treatment response\, relapse patterns and emerging research directions. \nSCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior\, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive\, with high response rates to first-line therapy\, relapse is common and subsequent responses are often short-lived. \nThe presentation highlighted current staging approaches\, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment\, patterns of relapse and the clinical distinction between sensitive and refractory disease\, which continues to guide second-line treatment decisions. \nKey takeaway: Despite high initial response rates\, SCLC remains a challenging disease with frequent relapses\, underscoring the need for timely diagnosis\, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.
URL:https://kesho-kenya.org/event/lung-cancer-treatment/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-10-at-1.44.04-PM-e1762785377526.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251030T190000
DTEND;TZID=Africa/Nairobi:20251030T203000
DTSTAMP:20260423T191025
CREATED:20251029T090350Z
LAST-MODIFIED:20251223T153247Z
UID:40485-1761850800-1761856200@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Hepatocellular Carcinoma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nMultidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited) \nDate: 30th October 2025Time: 7:00 PM – 8:30 PM EAT \nModerator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon\, Hercules Healthcare \nSpeakers: \n\nDr. Gladwell KiarieMedical Oncologist\, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends\nDr. Eric MurungaConsultant Physician\, Gastroenterologist; Chairman\, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings\nDr. Samuel NgukuConsultant\, Radiology and Nuclear Medicine\, Aga Khan University Hospital\, NairobiTopic: Imaging of Hepatocellular Carcinoma\n\nOrganized by:Kenya Society of Haematology & Oncology (KESHO) \nPartner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nThe Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates \nPresentations by Dr Gladwell Kiarie and Dr Eric Murunga \nTwo complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC)\, with a focus on pragmatic\, evidence-based approaches applicable to resource-limited settings. \nDr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma\, emphasizing the importance of stage-guided\, individualized care. Using established staging frameworks\, she highlighted how tumor burden\, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies\, including immunotherapy and targeted agents\, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making\, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC. \nDr Eric Murunga addressed the management of chronic Hepatitis B within real-world\, resource-constrained contexts. He outlined practical diagnostic pathways\, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools\, long-term antiviral therapy and structured follow-up. Preventive strategies including screening\, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer. \nTogether\, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease\, particularly viral hepatitis. \nKey takeaway: Strengthening early identification and treatment of chronic Hepatitis B\, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma\, is central to reducing advanced liver cancer and improving survival in resource-limited settings.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-hepatocellular-carcinoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-28-at-2.53.20-PM-e1761728953517.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251023T190000
DTEND;TZID=Africa/Nairobi:20251023T203000
DTSTAMP:20260423T191025
CREATED:20251022T122025Z
LAST-MODIFIED:20251022T124234Z
UID:40475-1761246000-1761251400@kesho-kenya.org
SUMMARY:Advancing Breast Cancer Survivorship Care in Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nTheme: Evidence\, Outcomes & Psychosocial PerspectivesDate: 23rd October 2025Time: 7:00 PM – 8:30 PM EATCPD Accredited \nSpeakers & Topics: \n1. Zahra Haji \n\nPsycho-oncologist & Associate Scientist\nPsychosocial Oncology Lead\, DART Lead Kenya; Aga Khan University Hospital Nairobi\nTopic: The Emotional Journey of Survivorship: Addressing Psychological Well-being after Breast Cancer\n\n2. Prisca Githuka \n\nVice-Chairperson & Advocacy Chair\, Kenyan Network of Cancer Organizations (KENCO); Chairlady\, Cancer Survivors Association of Kenya; Founder and Team Leader – Pink Hearts Cancer Support Foundation\nTopic: Lived Experience of Breast Cancer Survivors in Kenya: Gaps and Implications for Care\n\n3. Dr. Joyfrida Chepchumba \n\nPharmacist & Program Officer – Treatment\, Palliative Care and Survivorship Pillar\, National Cancer Control Program\nTopic: Policy Frameworks for Breast Cancer Survivorship Care in Kenya\n\n4. Lyagamula (Gammy) Kisia \n\nResearch Officer\, African Population and Health Research Center (APHRC)\, Kenya\nTopic: Breast Cancer Survivorship in Kenya: Key Findings from a Pilot Study\n\nModerator:  Dr. Miriam Mutebi\n\nConsultant Breast Surgical Oncologist & Health Systems Researcher\, Aga Khan University in Nairobi\, Kenya\n\nOrganizers & Partners:\n\nKESHO (Kenya Society of Hematology & Oncology)\nNCCP (National Cancer Control Programme)\nKILELE Health Association\nKENCO (Kenyan Network of Cancer Organizations)\nAPHRC (African Population and Health Research Center)\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_b8KShWmmTw6SEdqZgvXY6Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/advancing-breast-cancer-survivorship-care-in-kenya/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-22-at-12.24.06-AM-e1761135614607.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251021T190000
DTEND;TZID=Africa/Nairobi:20251021T203000
DTSTAMP:20260423T191025
CREATED:20251014T073256Z
LAST-MODIFIED:20251016T162549Z
UID:40451-1761073200-1761078600@kesho-kenya.org
SUMMARY:Digital Health: A Breast Cancer Journey
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\nDate: 21st October 2025\nTime: 7 PM – 8:30 PM (EAT)\nCPD Accredited\n\nModerator: \n\nDr. Sitna Ali Mwanzi – Consultant Medical Oncologist\, Kenyatta National Hospital\n\nSpeakers: \n\nDr. Matiko Riro – Health Economist & CEO\, Savannah Global Health Institute (SGHI)Topic: The Role of Data in Health Financing for Oncology – Use case Herceptin SC Access program\nDr. Ngure Nyaga – Healthcare Innovator & Technologist\, Savannah InformaticsTopic: Leveraging Digital Solutions\, Data & AI to Optimise Patient Outcomes in Oncology\nDr. Gladwell Kiarie – Medical Oncologist\, The Nairobi HospitalTopic: Optimising Outcomes in Cancer Care – The Breast Cancer Patient Journey\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_btn title=”ONLINE REGISTRATION” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_NwAtGBXoSgumue-28Yk7XA”][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_btn title=”PHYSICAL REGISTRATION FORM” color=”danger” css=”” link=”url:https%3A%2F%2Fforms.gle%2FqoV5reYJByoGNTi46″][/vc_column][vc_column width=”1/2″][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/a-breast-cancer-journey/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-16-at-4.37.46-PM-e1760631816635.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251015T080000
DTEND;TZID=Africa/Nairobi:20251015T170000
DTSTAMP:20260423T191025
CREATED:20251015T142554Z
LAST-MODIFIED:20251015T142716Z
UID:40467-1760515200-1760547600@kesho-kenya.org
SUMMARY:Advancing Care in HER2 Positive Breast Cancer
DESCRIPTION:Date: 9th October 2025\nTime: 7 PM – 8:30 PM (EAT)CPD Accredited\n\nSpeakers\n\n\nDr. Manel Haj MansourConsultant Medical Oncologist & Section Head of Medical Oncology\, Aga Khan University Hospital\, NairobiTopic: Early and Locally Advanced HER2 Positive Breast Cancer — Evolving Strategies in Diagnosis\, Treatment\, and Long-Term Outcomes. \n\n\nDr. Angela McligeyoPhysician and Medical OncologistTopic: Metastatic HER2 Positive Breast Cancer — Optimizing Outcomes Through Novel Therapies and Multidisciplinary Care. \n\n\nModerator\n\nDr. Catherine NyongesaDirector of Medical Services\, Kenyatta National Hospital & Co-founder\, Texas Cancer Centre\, Nairobi.
URL:https://kesho-kenya.org/event/advancing-care-in-her2-positive-breast-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-09-at-10.07.52-AM-e1760538332676.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251002T190000
DTEND;TZID=Africa/Nairobi:20251002T203000
DTSTAMP:20260423T191025
CREATED:20250930T124046Z
LAST-MODIFIED:20251223T171811Z
UID:40444-1759431600-1759437000@kesho-kenya.org
SUMMARY:Triple Negative Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nTriple Negative Breast Cancer: Early and Late Stage Management(CPD Accredited) \nDate & Time: \n\n2nd October 2025\n7 PM – 8:30 PM (EAT)\n\nSpeaker: Dr. Joseph AbuodhaConsultant Medical Oncologist\, Department of Haematology and Oncology\, Aga Khan University Hospital\, NairobiTopic: Triple-Negative Breast Cancer: Advancing Care Across Early and Late Stages \nModerator: Dr. Helena MusauConsultant Clinical/Radiation Oncologist and Palliative Care Specialist \nSummary: \nTriple-Negative Breast Cancer: Contemporary Clinical Updates\nPresentation by Dr Joseph Abuodha\n \nDr Joseph Abuodha\, Consultant Medical Oncologist\, delivered a comprehensive clinical update on the biology\, diagnosis and management of triple-negative breast cancer (TNBC)\, highlighting its aggressive nature\, molecular heterogeneity and disproportionate burden in African populations. \nThe presentation outlined the distinctive pathological and molecular characteristics of TNBC\, emphasizing the absence of hormone receptor and HER2 expression\, high-grade histology and frequent genomic instability. Local and global epidemiological data were reviewed\, underscoring the higher prevalence and mortality associated with TNBC in African and African-descended populations. \nManagement strategies across the disease spectrum were discussed\, with chemotherapy reaffirmed as the backbone of treatment in non-metastatic disease. Dr Abuodha highlighted the growing role of neoadjuvant therapy\, particularly for stage II and III disease\, noting that achievement of pathologic complete response (pCR) remains a critical prognostic marker. Evidence supporting the incorporation of platinum agents and immune checkpoint inhibitors in selected patients was reviewed\, alongside adjuvant strategies for residual disease\, including capecitabine and PARP inhibitors in BRCA-mutated cancers. \nIn the metastatic setting\, the importance of repeat biopsy and molecular reassessment was emphasized to guide therapy. Emerging systemic options including immunotherapy\, PARP inhibitors and antibody–drug conjugates were discussed in the context of treatment sequencing and patient selection\, alongside the central role of supportive and palliative care. \nKey takeaway: Triple-negative breast cancer requires a biologically informed\, stage-adapted treatment approach\, with increasing emphasis on neoadjuvant strategies\, molecular testing and integration of novel systemic therapies to improve outcomes in high-risk populations.
URL:https://kesho-kenya.org/event/triple-negative-breast-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-30-at-9.56.23-AM-e1759236176125.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250925T190000
DTEND;TZID=Africa/Nairobi:20250925T203000
DTSTAMP:20260423T191025
CREATED:20250923T090118Z
LAST-MODIFIED:20250923T091234Z
UID:40433-1758826800-1758832200@kesho-kenya.org
SUMMARY:Prostate Cancer Awareness
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\nTheme: Advancing Prostate Cancer Awareness\nDate: 25th September 2025\nTime: 7 PM – 8:30 PM EAT\n\nModerator: Prof. Mungai Ngugi (Consultant Urologist & Transplant Surgeon\, Upper Hill Medical Center & Director\, East Africa Kidney Institute) \nSpeakers: \n\nH.E. Prof. Peter Anyang’ Nyong’o (Governor\, Kisumu County)\nDr. Amina K. Habib (Medical Oncologist\, Aga Khan University Hospital\, Nairobi)\nProf. Nicholas Othieno Abinya (Professor of Medicine\, Medical Oncologist\, The Nairobi Hospital)\n\nOrganizers/Sponsors: \n\nKenya Society of Haematology & Oncology (KESHO)\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_QvPa4Ky7RoGRhd1f_yr2lw”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-awareness/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-23-at-11.03.20-AM-e1758618147859.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250918T190000
DTEND;TZID=Africa/Nairobi:20250918T203000
DTSTAMP:20260423T191025
CREATED:20250915T115752Z
LAST-MODIFIED:20250916T123756Z
UID:40417-1758222000-1758227400@kesho-kenya.org
SUMMARY:Management of CML Blast Crisis
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nMANAGEMENT OF CML Blast Crisis \n📅 Date: 18th September 2025⏰ Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Angela McligeyoPhysician and Medical Oncologist \nSPEAKERProfessor Gianantonio RostiIRCCS IRST “Dino Amadori”\, Meldola (Italy)Managing CML in Blast Crisis When Intensive Treatment Options are Available \nSPEAKERProfessor Malkit RiyatAssociate Professor of Haematology & Consultant Haematologist\, Aga Khan University Hospital\, NairobiManaging CML in Blast Crisis When Intensive Treatment Options are Limited \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=” Click to Register” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_dqr0xaQTQ4azL00zAgi9Aw”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cml-blast-crisis/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-16-at-11.46.45-AM-e1758026251987.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250911T190000
DTEND;TZID=Africa/Nairobi:20250911T203000
DTSTAMP:20260423T191025
CREATED:20250909T145133Z
LAST-MODIFIED:20250909T150805Z
UID:40404-1757617200-1757622600@kesho-kenya.org
SUMMARY:Palliative Support and Pain Management
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Moderator: \n\nDr. Zipporah Ali – Palliative Care Physician and Public Health Specialist\n\nSpeakers: \n\nDr. Lee Ngugi – Pain Management Specialist\, Anaesthesiologist & Lecturer\, Kenyatta University\, School of Medicine\, NairobiTopic: Interventional Pain Management Procedures in Cancer-Related Pain\nDr. Esther Munyoro – Neuro-anaesthetist & Palliative Care Specialist\, Former Head of Pain and Palliative Care Unit\, Kenyatta National Hospital\, NairobiTopic: Palliative care: Making it real\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=””][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/support-and-pain-management/
CATEGORIES:Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-09-at-1.11.19-PM-e1757429658184.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250904T190000
DTEND;TZID=Africa/Nairobi:20250904T203000
DTSTAMP:20260423T191025
CREATED:20250902T070734Z
LAST-MODIFIED:20250902T074433Z
UID:40392-1757012400-1757017800@kesho-kenya.org
SUMMARY:Paediatric Bone Marrow Transplantation
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nDate & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT) \nModerator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist\,MP Shah Hospital\, Nairobi \nSpeaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist\,Gertrude’s Children’s Hospital\, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities \n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_4YrYt-keT5yLYGrVG-811Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bone-marrow-transplantation/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-02-at-9.30.03-AM-e1756796966321.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250828T190000
DTEND;TZID=Africa/Nairobi:20250828T193000
DTSTAMP:20260423T191025
CREATED:20250828T155020Z
LAST-MODIFIED:20250828T160124Z
UID:40384-1756407600-1756409400@kesho-kenya.org
SUMMARY:Cancer Care
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nModerator: \n\nDr. Anne Mwirigi – Consultant Haematologist & Assistant Professor\, Aga Khan University Hospital\, Nairobi\n\nSpeakers: \n\nDr. Arjun Ghosh – Consultant Cardiologist\, Barts Heart Centre (BHC)\, St. Bartholomew’s Hospital\, London & University College London Hospital\nDr. Manel Haj Mansour – Consultant Medical Oncologist & Section Head of Medical Oncology\, Aga Khan University Hospital\, Nairobi\nDr. Charles Kariuki – Interventional Cardiologist\, Ubora Heart\, The Nairobi Hospital\nDr. Gladwell Kiarie – Medical Oncologist\, The Nairobi Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_8tHcTBq9RQyHW5ptZ_-OdA”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-care/
CATEGORIES:CME 2023,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-28-at-7.05.53-AM-e1756396849381.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250807T190000
DTEND;TZID=Africa/Nairobi:20250807T203000
DTSTAMP:20260423T191025
CREATED:20250805T170900Z
LAST-MODIFIED:20250805T174804Z
UID:40344-1754593200-1754598600@kesho-kenya.org
SUMMARY:Cervical Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nSpeakers:\n\nDr. Dulcie Wanda\n\n\nClinical & Radiation Oncologist\nHead of Department\, Nakuru Regional Cancer Treatment Centre\n\nTopic: Radiotherapy in Management of Advanced Cancer of the Cervix. \n2. Dr. Edward Sang \n\nGynaecologist and Oncologist\, MP Shah Doctors Plaza\, Nairobi\n\nTopic: Surgical Techniques in Cervical Cancer \nModerator:\nDr. Afrin Fatima Shaffi \n\nGynecologic Oncologist\, Nairobi West Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_KINXix7MSqys9Q4p_rWZhQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cervical-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-05-at-4.13.55-PM-1-e1754414483969.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250731T190000
DTEND;TZID=Africa/Nairobi:20250731T203000
DTSTAMP:20260423T191025
CREATED:20250414T202143Z
LAST-MODIFIED:20250806T123353Z
UID:24416-1753988400-1753993800@kesho-kenya.org
SUMMARY:Bone Marrow Transplant
DESCRIPTION:Date: 31 July 2025 | 7:00 – 8:30PM EAT \nModerator: Dr Matilda Ongondi \nDr. Rohini Radia – Bone Marrow Transplantation  \nBone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up. \nThere are two main types: \nAutologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD)\, infections\, and infertility\, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas. \nPatient and donor selection\, conditioning protocols\, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential\, especially due to chronic GVHD and relapse risks. In sickle cell disease\, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration. \nSuccess in BMT depends on early identification\, thorough preparation\, and sustained multidisciplinary care beyond the immediate post-transplant period.
URL:https://kesho-kenya.org/event/bone-marrow-transplant/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250801-WA0000-e1754042861975.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250724T190000
DTEND;TZID=Africa/Nairobi:20250724T203000
DTSTAMP:20260423T191025
CREATED:20250414T201502Z
LAST-MODIFIED:20250806T120327Z
UID:24407-1753383600-1753389000@kesho-kenya.org
SUMMARY:Sarcoma Care
DESCRIPTION:Bridging Gaps in Soft Tissue Sarcoma Care \nDate: 24 July 2025 | 7:00 – 8:30pm EAT \nModerator: Dr Rose Munge \nDr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa\nSoft tissue sarcomas are rare malignant tumors of mesenchymal origin\, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm)\, high recurrence (78%)\, and better outcomes with radical excisions. \nChemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However\, access to radiotherapy remains limited\, impacting outcomes. Timely radiotherapy\, as seen in Tanzania\, improves survival. \nKey gaps include limited resources\, lack of local treatment guidelines\, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers\, local research\, and developing Africa-specific management guidelines.
URL:https://kesho-kenya.org/event/sarcoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Sarcoma-Care-e1754481435270.jpg
END:VEVENT
END:VCALENDAR